Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. CHICAGO / Jul 08, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next , into breast cancer. Since its launch in 2024, Tempus Next has... Read More